Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer
ConclusionsXpert has an improved NPV compared with UroVysion and cytology in patients under follow-up for BC. It represents a promising tool for excluding BC in these patients, reducing the need for cystoscopy.Patient summaryXpert is an easy-to-perform urine test with good performance compared with standard urine tests. It should help optimize the follow-up of recurrent bladder cancer patients.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cystoscopy | Cytology | Immunotherapy | Smokers | Statistics | Urology & Nephrology